At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
UCB7665drug
Likely dose
UCB7665 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
In Brief
A Phase 2 clinical trial evaluating UCB7665 for Thrombocytopenia. Completed, enrolled 66 participants across 29 sites in 11 countries.
Detailed Summary
The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombocytopenia
CountriesAustralia, Bulgaria, Czechia, Georgia, Germany, Italy, Moldova, Poland, Romania, Spain, United Kingdom
CollaboratorsParexel
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedMar 2016
Primary CompletionFeb 2019
TodayJul 2026
First PostedMar 24, 2016
Enrollment StartMar 2, 2016
Primary CompletionFeb 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.3 years ago
Interventions
UCB7665drug
* Intervention Type: Biological/Vaccine * Pharmaceutical Form: Powder for solution for infusion * Concentration: 100 mg/ml - Route of Administration: Subcutaneous infusion